Quote:

---

That study is meant to clarify the correct dosing of leronlimab in the MASH setting and address the question of potential synergy with Resmetirom, the only currently approved therapy for the treatment of MASH.“

Anyone else looking forward to this? If the results are good this could mean a phase 3 combo with their company?

---

How that plays out depends on how the study is set up. It could have a resmetirom arm, a resmetirom + 350mg leronlimab arm, a resmetirom + 700mg arm and placebo. That would show the synergy with resmetirom but could muddy things for correct dosing and would not show if resmetirom is unnecessary.

The best way to do it is to first have a 350mg leronlimab arm, 700mg leronlimab arm and placebo and sort out dosage first. Then do a resmetirom + best dosage leronlimab arm, a best dosage leronlimab arm, a resmetirom arm and a placebo arm. That way you have all bases covered and can show leronlimab equals resmetirom +leronlimab and beats resmetirom itself.